Systemic scleroderma

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
1 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 2
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
Monoclonal antibody 1 substance
Phase II: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

2 trials
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-510380-34-00 10 countries 2024 n=78
    Recruiting
  • Novartis Pharma AG Commercial
    IANALUMAB
    2024-511933-36-00 10 countries 2025 n=62
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase II 1
New trials by year
2024
1
2025
1
← All indication landscapes